Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for OCUL

Stock Name	Ocular Therapeutix Inc
Ticker	OCUL(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US67576A1007
LEI	529900ABAWFXOHSIHG03

Show aggregate OCUL holdings

News associated with OCUL

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.20 Consensus Target Price from Brokerages: Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has been given an average recommendation of “Buy” by the five ratings firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued ratings on the stock […] - 2025-09-09 02:46:48
XTX Topco Ltd Increases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL): XTX Topco Ltd raised its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 95.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,605 shares of the biopharmaceutical company’s stock after buying an additional 11,012 shares during the quarter. […] - 2025-08-14 04:25:01
Needham & Company LLC Boosts Ocular Therapeutix (NASDAQ:OCUL) Price Target to $15.00: Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) had its target price upped by investment analysts at Needham & Company LLC from $14.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential […] - 2025-08-07 04:30:57
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.33 Consensus PT from Analysts: Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in […] - 2025-08-07 03:12:45
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down Following Weak Earnings: Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) gapped down prior to trading on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $12.35, but opened at $11.21. Ocular Therapeutix shares last traded at $11.34, with a volume of 558,460 shares traded. The biopharmaceutical company reported ($0.39) earnings per share […] - 2025-08-07 02:13:01
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Allianz Asset Management GmbH: Allianz Asset Management GmbH lowered its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 41.9% during the first quarter, Holdings Channel.com reports. The fund owned 37,500 shares of the biopharmaceutical company’s stock after selling 27,000 shares during the quarter. Allianz Asset Management GmbH’s holdings in Ocular Therapeutix were worth $275,000 at the end […] - 2025-08-04 05:58:51
Nuveen Asset Management LLC Sells 88,468 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL): Nuveen Asset Management LLC decreased its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 17.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 414,104 shares of the biopharmaceutical company’s stock after selling 88,468 shares during the period. Nuveen Asset Management LLC’s holdings in Ocular Therapeutix were worth $3,536,000 as […] - 2025-06-02 05:04:52
Millennium Management LLC Acquires New Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL): Millennium Management LLC acquired a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 447,237 shares of the biopharmaceutical company’s stock, valued at approximately $3,819,000. A number of other hedge […] - 2025-05-30 05:40:53
Bank of America Corp DE Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL): Bank of America Corp DE lessened its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 43.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 437,071 shares of the biopharmaceutical company’s stock after selling 341,400 shares during the quarter. Bank […] - 2025-05-30 04:54:54
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by ProShare Advisors LLC: ProShare Advisors LLC raised its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 32.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,270 shares of the biopharmaceutical company’s stock after purchasing an additional 12,669 shares during the period. […] - 2025-05-28 08:08:48
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 2,853 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 3.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 88,463 shares of the biopharmaceutical company’s stock after buying an additional 2,853 shares during the quarter. MIRAE […] - 2025-05-28 05:31:02
D. E. Shaw & Co. Inc. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL): D. E. Shaw & Co. Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 31,419 shares of the biopharmaceutical company’s stock, valued at approximately $268,000. A number of other hedge funds and other institutional investors also recently modified their holdings of […] - 2025-05-28 04:42:56
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Deutsche Bank AG: Deutsche Bank AG lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 45.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 456,120 shares of the biopharmaceutical company’s stock after selling 377,454 shares during the period. Deutsche Bank […] - 2025-05-20 05:12:53
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 6.5% After Analyst Downgrade: Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report)’s share price fell 6.5% during trading on Tuesday after Needham & Company LLC lowered their price target on the stock from $15.00 to $14.00. Needham & Company LLC currently has a buy rating on the stock. Ocular Therapeutix traded as low as $7.31 and last traded at […] - 2025-05-07 03:05:15
First Trust Advisors LP Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL): First Trust Advisors LP bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) during the 4th quarter, Holdings Channel reports. The fund bought 212,944 shares of the biopharmaceutical company’s stock, valued at approximately $1,819,000. A number of other institutional investors and hedge funds have also made changes to their positions […] - 2025-05-06 04:58:55
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Acquired by CANADA LIFE ASSURANCE Co: CANADA LIFE ASSURANCE Co lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 152.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,227 shares of the biopharmaceutical company’s stock after buying an additional 18,251 […] - 2025-05-01 06:12:45
XTX Topco Ltd Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL): XTX Topco Ltd bought a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,593 shares of the biopharmaceutical company’s stock, valued at approximately $99,000. Several other hedge funds have also bought and sold shares of OCUL. […] - 2025-04-30 06:12:51
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Barclays PLC: Barclays PLC decreased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 35.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 331,242 shares of the biopharmaceutical company’s stock after selling 180,280 shares during the period. Barclays PLC’s holdings in Ocular […] - 2025-04-30 05:12:50
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Cut by Legal & General Group Plc: Legal & General Group Plc lowered its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 8.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 104,783 shares of the biopharmaceutical company’s stock after selling 9,296 shares during the quarter. Legal […] - 2025-04-28 04:56:53
Invesco Ltd. Acquires 134,573 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL): Invesco Ltd. raised its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 17.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 890,046 shares of the biopharmaceutical company’s stock after acquiring an additional 134,573 shares during the period. […] - 2025-04-25 04:58:59
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $16.38 Average PT from Analysts: Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price […] - 2025-04-04 02:45:04
Cibc World Markets Corp Invests $124,000 in Ocular Therapeutix, Inc. (NASDAQ:OCUL): Cibc World Markets Corp purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 14,562 shares of the biopharmaceutical company’s stock, valued at approximately $124,000. Several other large investors have also modified their holdings of the stock. AlphaQuest LLC acquired […] - 2025-03-28 06:18:49
Ocular Therapeutix (NASDAQ:OCUL) Coverage Initiated at Royal Bank of Canada: Equities researchers at Royal Bank of Canada started coverage on shares of Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) in a report released on Tuesday, Marketbeat reports. The firm set an “outperform” rating and a $17.00 price target on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would indicate a potential upside of […] - 2025-03-20 04:48:56
Needham & Company LLC Begins Coverage on Ocular Therapeutix (NASDAQ:OCUL): Analysts at Needham & Company LLC initiated coverage on shares of Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) in a report issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $15.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective indicates a potential upside of 77.94% from […] - 2025-03-13 04:22:56
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of “Moderate Buy” by Analysts: Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 […] - 2025-03-07 05:14:55
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down Following Weak Earnings: Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) shares gapped down prior to trading on Monday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $7.14, but opened at $6.94. Ocular Therapeutix shares last traded at $6.45, with a volume of 361,162 shares changing hands. The biopharmaceutical company reported […] - 2025-03-05 04:34:51
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Acquired by New York State Common Retirement Fund: New York State Common Retirement Fund lifted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 18.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 98,097 shares of the biopharmaceutical company’s stock after purchasing an additional 15,239 shares during the quarter. New York State Common Retirement Fund’s holdings in […] - 2025-03-04 07:17:07
Investors Buy High Volume of Call Options on Ocular Therapeutix (NASDAQ:OCUL): Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) was the target of unusually large options trading activity on Monday. Stock traders bought 7,643 call options on the stock. This represents an increase of approximately 1,707% compared to the typical volume of 423 call options. Ocular Therapeutix Price Performance Shares of NASDAQ OCUL opened at $5.93 […] - 2025-03-04 06:44:54
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Position Lifted by Rhumbline Advisers: Rhumbline Advisers increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 2.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 213,601 shares of the biopharmaceutical company’s stock after buying an additional 5,682 shares during the period. Rhumbline Advisers’ holdings in Ocular Therapeutix were worth $1,824,000 as of its most recent […] - 2025-03-04 06:12:53
Analysts See 19% Gains Ahead For FYX: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-01-30 10:31:08

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc OCUL holdings

Date	Number of OCUL Shares Held	Base Market Value of OCUL Shares	Local Market Value of OCUL Shares	Change in OCUL Shares Held	Change in OCUL Base Value	Current Price per OCUL Share Held	Previous Price per OCUL Share Held
2025-09-26 (Friday)	35,792	USD 448,474	USD 448,474
2025-09-25 (Thursday)	35,792	USD 438,094	USD 438,094	0	USD -11,454	USD 12.24	USD 12.56
2025-09-24 (Wednesday)	35,792	USD 449,548	USD 449,548
2025-09-17 (Wednesday)	35,560	USD 432,587	USD 432,587	0	USD -9,602	USD 12.165	USD 12.435
2025-09-16 (Tuesday)	35,560	USD 442,189	USD 442,189
2025-09-12 (Friday)	35,328	USD 452,552	USD 452,552
2025-09-11 (Thursday)	35,328	USD 451,139	USD 451,139

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of OCUL by Blackrock for IE00B3VWM098

Show aggregate share trades of OCUL

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -116 12.130* 8.55 Profit of 992 on sale
2025-07-31 BUY 348 11.580* 8.51
2025-06-30 SELL -232 9.280* 8.23 Profit of 1,909 on sale
2025-06-25 SELL -116 9.190* 8.21 Profit of 952 on sale
2025-06-20 SELL -232 8.130* 8.20 Profit of 1,902 on sale
2025-05-30 BUY 13,069 8.010* 8.16
2025-05-23 BUY 71 7.300* 8.18
2025-05-19 SELL -71 7.510* 8.21 Profit of 583 on sale
2025-05-15 SELL -213 7.170* 8.23 Profit of 1,752 on sale
2025-05-12 SELL -71 7.390* 8.26 Profit of 586 on sale
2025-05-09 SELL -71 7.060* 8.27 Profit of 587 on sale
2025-04-30 SELL -71 8.300* 8.29 Profit of 589 on sale
2025-04-24 SELL -142 7.900* 8.31 Profit of 1,180 on sale
2025-04-17 SELL -71 7.310* 8.34 Profit of 592 on sale
2025-04-15 SELL -213 7.530* 8.37 Profit of 1,782 on sale
2025-04-14 SELL -213 7.570* 8.37 Profit of 1,784 on sale
2025-04-09 SELL -284 6.840* 8.43 Profit of 2,393 on sale
2025-04-07 SELL -497 6.300* 8.48 Profit of 4,214 on sale
2025-04-04 SELL -710 6.355* 8.50 Profit of 6,038 on sale
2025-03-31 BUY 71 7.330* 8.56
2025-03-19 SELL -142 7.700* 8.66 Profit of 1,229 on sale
2025-03-14 SELL -426 7.720* 8.70 Profit of 3,705 on sale
2025-03-13 SELL -142 7.880* 8.71 Profit of 1,237 on sale
2025-03-12 SELL -2,414 8.430* 8.71 Profit of 21,034 on sale
2025-03-07 SELL -142 7.540* 8.75 Profit of 1,242 on sale
2025-03-06 SELL -213 7.340* 8.77 Profit of 1,868 on sale
2025-03-03 SELL -71 5.925* 8.88 Profit of 630 on sale
2025-02-28 SELL -426 7.140* 8.91 Profit of 3,794 on sale
2025-02-26 SELL -71 6.940* 8.97 Profit of 637 on sale
2025-02-25 SELL -213 6.770* 9.01 Profit of 1,919 on sale
2025-02-18 BUY 355 7.200* 9.22
2025-02-13 BUY 71 7.480* 9.33
2025-02-12 BUY 71 7.455* 9.37
2025-02-11 BUY 213 7.440* 9.41
2025-02-06 BUY 639 7.640* 9.53
2025-01-27 BUY 71 7.890* 9.90
2024-12-30 BUY 355 8.350* 10.10
2024-12-06 BUY 284 9.620* 10.17
2024-12-05 BUY 71 9.180* 10.20
2024-12-04 BUY 355 9.480* 10.23
2024-11-29 BUY 355 9.890* 10.29
2024-11-27 BUY 284 10.060* 10.31
2024-11-26 BUY 71 9.750* 10.33
2024-11-21 BUY 355 8.520* 10.57
2024-11-20 BUY 213 8.780* 10.67
2024-11-18 BUY 852 8.690* 10.91
2024-11-12 BUY 568 10.600* 10.93
2024-11-08 BUY 355 11.100* 10.91
2024-11-07 BUY 1,065 10.780* 10.92
2024-11-06 BUY 142 10.940* 10.92
2024-10-31 BUY 71 10.530* 11.16
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-116	12.130*	8.55 Profit of 992 on sale
2025-07-31	BUY	348	11.580*	8.51
2025-06-30	SELL	-232	9.280*	8.23 Profit of 1,909 on sale
2025-06-25	SELL	-116	9.190*	8.21 Profit of 952 on sale
2025-06-20	SELL	-232	8.130*	8.20 Profit of 1,902 on sale
2025-05-30	BUY	13,069	8.010*	8.16
2025-05-23	BUY	71	7.300*	8.18
2025-05-19	SELL	-71	7.510*	8.21 Profit of 583 on sale
2025-05-15	SELL	-213	7.170*	8.23 Profit of 1,752 on sale
2025-05-12	SELL	-71	7.390*	8.26 Profit of 586 on sale
2025-05-09	SELL	-71	7.060*	8.27 Profit of 587 on sale
2025-04-30	SELL	-71	8.300*	8.29 Profit of 589 on sale
2025-04-24	SELL	-142	7.900*	8.31 Profit of 1,180 on sale
2025-04-17	SELL	-71	7.310*	8.34 Profit of 592 on sale
2025-04-15	SELL	-213	7.530*	8.37 Profit of 1,782 on sale
2025-04-14	SELL	-213	7.570*	8.37 Profit of 1,784 on sale
2025-04-09	SELL	-284	6.840*	8.43 Profit of 2,393 on sale
2025-04-07	SELL	-497	6.300*	8.48 Profit of 4,214 on sale
2025-04-04	SELL	-710	6.355*	8.50 Profit of 6,038 on sale
2025-03-31	BUY	71	7.330*	8.56
2025-03-19	SELL	-142	7.700*	8.66 Profit of 1,229 on sale
2025-03-14	SELL	-426	7.720*	8.70 Profit of 3,705 on sale
2025-03-13	SELL	-142	7.880*	8.71 Profit of 1,237 on sale
2025-03-12	SELL	-2,414	8.430*	8.71 Profit of 21,034 on sale
2025-03-07	SELL	-142	7.540*	8.75 Profit of 1,242 on sale
2025-03-06	SELL	-213	7.340*	8.77 Profit of 1,868 on sale
2025-03-03	SELL	-71	5.925*	8.88 Profit of 630 on sale
2025-02-28	SELL	-426	7.140*	8.91 Profit of 3,794 on sale
2025-02-26	SELL	-71	6.940*	8.97 Profit of 637 on sale
2025-02-25	SELL	-213	6.770*	9.01 Profit of 1,919 on sale
2025-02-18	BUY	355	7.200*	9.22
2025-02-13	BUY	71	7.480*	9.33
2025-02-12	BUY	71	7.455*	9.37
2025-02-11	BUY	213	7.440*	9.41
2025-02-06	BUY	639	7.640*	9.53
2025-01-27	BUY	71	7.890*	9.90
2024-12-30	BUY	355	8.350*	10.10
2024-12-06	BUY	284	9.620*	10.17
2024-12-05	BUY	71	9.180*	10.20
2024-12-04	BUY	355	9.480*	10.23
2024-11-29	BUY	355	9.890*	10.29
2024-11-27	BUY	284	10.060*	10.31
2024-11-26	BUY	71	9.750*	10.33
2024-11-21	BUY	355	8.520*	10.57
2024-11-20	BUY	213	8.780*	10.67
2024-11-18	BUY	852	8.690*	10.91
2024-11-12	BUY	568	10.600*	10.93
2024-11-08	BUY	355	11.100*	10.91
2024-11-07	BUY	1,065	10.780*	10.92
2024-11-06	BUY	142	10.940*	10.92
2024-10-31	BUY	71	10.530*	11.16

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of OCUL

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	199,268	1,000	563,052	35.4%
2025-09-18	200,963	0	877,767	22.9%
2025-09-17	202,758	0	593,708	34.2%
2025-09-16	269,642	0	1,012,784	26.6%
2025-09-15	315,716	0	1,015,688	31.1%
2025-09-12	257,181	0	449,331	57.2%
2025-09-11	235,215	53	393,204	59.8%
2025-09-10	353,691	0	661,751	53.4%
2025-09-09	361,882	1,400	905,142	40.0%
2025-09-08	559,741	0	895,713	62.5%
2025-09-05	1,246,912	2,991	1,994,815	62.5%
2025-09-04	731,065	12,226	1,009,961	72.4%
2025-09-03	971,613	176	1,686,753	57.6%
2025-09-02	297,495	4,800	924,806	32.2%
2025-08-29	573,212	1,116	1,118,419	51.3%
2025-08-28	409,131	0	736,253	55.6%
2025-08-27	417,094	751	1,039,252	40.1%
2025-08-26	223,424	0	618,167	36.1%
2025-08-25	130,190	100	294,488	44.2%
2025-08-22	154,203	34,249	426,128	36.2%
2025-08-21	165,854	10,809	442,267	37.5%
2025-08-20	218,127	0	724,340	30.1%
2025-08-19	188,782	63	775,485	24.3%
2025-08-18	236,129	1,100	977,727	24.2%
2025-08-15	247,574	10,800	629,485	39.3%
2025-08-14	213,861	9,244	601,764	35.5%
2025-08-13	315,390	48,986	1,056,996	29.8%
2025-08-12	413,117	10,441	1,133,947	36.4%
2025-08-11	442,676	4,571	1,061,487	41.7%
2025-08-08	549,370	318	1,002,254	54.8%
2025-08-07	703,185	0	1,109,188	63.4%
2025-08-06	586,343	75,232	1,438,850	40.8%
2025-08-05	1,091,443	95,147	1,920,728	56.8%
2025-08-04	493,427	40,915	766,312	64.4%
2025-08-01	314,220	128	684,928	45.9%
2025-07-31	331,687	125	585,777	56.6%
2025-07-30	282,020	0	523,030	53.9%
2025-07-29	270,281	400	674,777	40.1%
2025-07-28	347,122	0	895,600	38.8%
2025-07-25	327,608	0	641,321	51.1%
2025-07-24	286,987	5,057	447,384	64.1%
2025-07-23	369,500	3,513	608,535	60.7%
2025-07-22	301,320	700	497,200	60.6%
2025-07-21	402,793	6,418	1,200,632	33.5%
2025-07-18	322,745	14	630,241	51.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE